Eluforsen - ProQR Therapeutics

Drug Profile

Eluforsen - ProQR Therapeutics

Alternative Names: QR 10; QR-010

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProQR Therapeutics
  • Class Antifibrotics; Oligoribonucleotides
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 28 Feb 2018 ProQR Therapeutics plans a phase II trial for Cystic fibrosis in North America, European Union and other countries in 2018
  • 24 Oct 2017 Updated efficacy data from a phase Ib trial in Cystic fibrosis released by ProQR Therapeutics
  • 25 Sep 2017 Topline efficacy data from a phase Ib trial in Cystic fibrosis released by ProQR Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top